Print

US Department of Health and Human Services Grants Orphan Drug Status to BioCancell Therapeutics's Ovarian Cancer Drug  
8/24/2009 10:57:06 AM

TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies (PK: TIKRF) today announced that the United States (“US”) Department of Health and Human Services ("HHS") has granted orphan drug status to BioCancell's BC-819 drug, currently in Phase I/IIa clinical trials, for its use in treating ovarian cancer.
//-->